Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis

Table 2 Therapy received by groups

	CNI, n = 86	CTX, n = 86	RTX, n = 86
Total follow-up duration, mo	12 (10.5, 18)	12 (12, 18)	12 (12, 18)
Total treatment period, mo	10 (6, 13)	9 (6, 12)	6 (1, 10.5)
Cumulative administration dose, g	N/A	6.6 ± 0.3	1.9 ± 0.1

Data were shown as median (IQR) or mean ± SD. CNI, calcineurin inhibitor; CTX, cyclophosphamide; RTX, rituximab; N/A not applicable

ISSN: 1471-2369